Rapid Progressive Course of Naja Naja Oxiana-bitten Patient

Document Type : Case Report


1 Department of Chemistry, Faculty of Science, Payame Noor University, Mashhad, Iran & School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

2 Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Veterinary Faculty of Islamic Azad University, Science and Research Branch, Tehran, Iran


Cases of snakebites especially with an elapidae are considered as a medical emergency. However, in some cases of elapidae envenomation, bite signs might be unpredictable.
Case: Dorsal surface of the second finger of a 39-year-old man was bitten by N. Naja Oxiana less than half hour before his admission. On arrival, patient had clear bilateral ptosis, mydriasis, reduced light reflex of pupils and sialorrhea. Other muscles power had no problem. The patient was agitated due to suffocation secondary to respiratory muscle paralysis, during half hours of hospitalization. He was intubated and mechanically ventilated. He was treated by antivenom, 10 vials as attack dose, 5 vials as repeated dose that was repeated three times and 2 vials every 8 hours as maintenance dose. He received antibiotic for local superinfection. Although, he did not receive any acetylcholinesterase inhibitors, he was extubated 48 hours later. The patient was discharged on the 7th day in good general condition with oral antibiotic prescription and no complication except local cellulitis. In conclusion, for efficient treatment of patients bitten with elapidae, we need to find the best course of treatment using the adequate antivenom as fast as possible.


  1. Monzavi SM, Dadpour B, Afshari R. Snakebite management in Iran: Devising a protocol. J Res Med Sci. 2014; 19(2):153-63. PMID: 24778670.
  2. Wang W, Chen QF, Yin RX, Zhu JJ, Li QB, Chang HH, et al. Clinical features and treatment experience: a review of 292 Chinese cobra snakebites. Environ Toxicol Pharmacol. 2014; 37(2):648-55. doi: 10.1016/j.etap.2013.
  3. Brent Critical care toxicology: diagnosis and management of the critically poisoned patient. In Burkhart KK, Dargan P, Hatten B, Megarbane B, Palmer R, Whit J (esd). Overview of snake envenoming. New York: Springer; 2017. P. 2279-318.
  4. Sintiprungrat K, Watcharatanyatip K, Senevirathne WD, Chaisuriya P, Chokchaichamnankit D, Srisomsap C, et al. A comparative study of venomics of Naja naja from India and Sri Lanka, clinical manifestations and antivenomics of an Indian polyspecific antivenom. J Proteomics. 2016; 132:131-43. doi: 10.1016/j.jprot.2015.10.007.
  5. Prasarnpun S, Walsh J, Harris JB. Beta-bungarotoxin-induced depletion of synaptic vesicles at the mammalian neuromuscular junction. Neuropharmacology. 2004; 47(2): 304-14. doi: 10.1016/j.neuropharm.2004.04.012.
  6. Dixon RW, Harris JB. Nerve terminal damage by beta-bungarotoxin: its clinical significance. Am J Pathol. 1999; 154(2):447-55. doi: 10.1016/s0002-9440(10)65291-1.
  7. Hung DZ, Liau MY, Lin-Shiau SY. The clinical significance of venom detection in patients of cobra snakebite. Toxicon. 2003; 41(4):409-15. doi:1016/S0041-0101(02)00336-7.
  8. Ranawaka UK, Lalloo DG, de Silva HJ. Neurotoxicity in snakebite the limits of our knowledge. PLoS Negl Trop Dis. 2013; 7(10): e2302. doi: 10.1371/journal.pntd.0002302.
  9. Warrell, D.A. Clinical toxicology of snakebite in Africa and the Middle East/Arabian Peninsula. In Handbook of clinical toxicology of animal venoms and poisons. Boca Raton, FL, USA: CRC Press. 1995; P. 433-492.
  10. Grishin EV, Sukhikh AP, Lukyanchuk NN, Slobodyan LN, Lipkin VM, Ovchinnikov YuA, et al. Amino acid sequence of neurotoxin II from Naja naja oxiana venom. FEBS Lett. 1973; 36(1):77-8. doi: 10.1016/0014-5793(73) 80340-0.